Khalili Hossein, Shojaei Lida, Mohammadi Mostafa, Beigmohammadi Mohammad-Taghi, Abdollahi Alireza, Doomanlou Mahsa
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
J Comp Eff Res. 2018 Sep;7(9):901-911. doi: 10.2217/cer-2018-0037. Epub 2018 Sep 7.
Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii.
47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes.
Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively.
In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.
在治疗鲍曼不动杆菌所致呼吸机相关性肺炎方面，尚未对黏菌素和氨苄西林-舒巴坦的疗效进行比较。在治疗耐碳青霉烯类鲍曼不动杆菌所致呼吸机相关性肺炎方面，比较了黏菌素和氨苄西林-舒巴坦联合美罗培南的疗效。
47例耐碳青霉烯类鲍曼不动杆菌所致呼吸机相关性肺炎患者被随机分为两组，分别接受美罗培南/黏菌素或美罗培南/氨苄西林-舒巴坦治疗14天。将临床和微生物学反应以及28天死亡率视为观察指标。
美罗培南/黏菌素组和美罗培南/氨苄西林-舒巴坦组的临床反应（分别为75%对69.6%；p = 0.75）和微生物清除率（分别为87.50%对91.3%；p = 0.59）相当。
在本研究中，美罗培南/黏菌素组和美罗培南/氨苄西林-舒巴坦组的临床和微生物学反应相当。
